Search the Newsreel

Exelon stock holds steady as regulated utility model underpins long-term earnings

Exelon (EXC) stock is viewed as a stable investment due to its regulated electric and gas utility model, which provides predictable earnings driven by rate cases, grid investments, and a diversified operational footprint. The company's focus on regulated operations, rate-base growth, and a disciplined …

What's Driving Exelixis' Recent Momentum and 2026 Outlook

Exelixis is experiencing strong growth driven by its flagship drug Cabometyx, which recently received label expansion into neuroendocrine tumors. The company's next-generation TKI, zanzalintinib, is a critical future asset with potential FDA approval in metastatic colorectal cancer by December 2026 and promising Phase 3 …

Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?

Is Exelixis (EXEL) Undervalued Or Already Priced In On Its Oncology Growth Story?

Exelixis closes 0.7% below its high as volume improves, while biotech momentum runs hotter

EXEL added 5.5% for the week on 18.2M shares, keeping its 13-week Trend Signal active, but the move comes with valuation distance and a neutral expectancy read.

Exelixis (EXEL) Up 6% Since Last Earnings Report: Can It Continue?

Why Exelixis (EXEL) Is Up 9.0% After Strong Q1 2026 Earnings And New Buyback Program

EXEL Q1 Earnings Top Estimates, Colorectal Cancer Drug in Focus

Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update

Exelixis (EXEL) Tops Q1 Earnings Estimates

EXEL Q4 Earnings and Revenues Beat, Colorectal Cancer Drug in Focus

Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update

Dexelance S.p.A.: analisi fondamentale e valutazioni finanziarie DEX | IT0005543480

BDR Exelon - E1XC34 - Resultados, Dividendos, Cotação e Indicadores

Stock Exelon - Stock EXC - Resultados, Dividendos, Cotação e Indicadores